An observational study in COVID-19 and Sars-CoV-2 Infection, sponsored by Ospedale Generale Di Zona Moriggia-Pelascini. Completed at 1 site in Italy. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-03.
Sponsored by Ospedale Generale Di Zona Moriggia-Pelascini · Observational
Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.
Among the 392 studies in COVID-19 with a site in Italy, this one is the 226th largest by enrollment of the 238 observational ones that give a count, is one of 98 that started in 2021, is one of 238 observational ones, and was the 288th registered.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
Browse COVID-19 studies →37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Italy, United States, Brazil and 4 more countries
Ages 18–65
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18–99 · Women only
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
IRCCS Sacro Cuore Don Calabria di Negrar · Sites in Italy
Ages 18+ · Healthy volunteers
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 COVID-19 studies recruiting now, 207 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 136 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
392 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 53 · Phase 3 53 · Phase 4 3
First in 2009; this study’s year is marked. 98 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Median enrollment 100 across the 153 interventional studies, 251 across the 238 observational. Of the 235 that completed or were terminated, 29 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 392 have an industry lead sponsor. The 10 most frequent:
Ospedale Generale Di Zona Moriggia-Pelascini is the lead sponsor of 36 studies on the registry; none are open to participants now.
Ospedale Generale Di Zona Moriggia-Pelascini has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
7 of the studies in COVID-19 with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05188612University of BolognaInternational Survey of Acute Coronavirus Syndromes-COVID-19 | 2026-12-31 |
| NCT06070961Fondazione Italiana Linfomi - ETSProspective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | 2027-05 |
Among the 392 studies in COVID-19 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recent studies suggest cognitive, emotional and behavioural impairments occur in patients after SARS-CoV-2 infection. Problems with memory, attention, information processing and executive functions are particularly prevalent in these patients, probably due to hypothesised sensitivity of the hippocampus to the virus. Cognitive impairment is also present in patients with no neurological, neuropsychological and neuropsychiatric history. Therefore, the aim of the present study is to describe neuropsychological and neuropsychiatric features in patients recovered from moderate to severe forms of Covid-19 some weeks after hospital dismission.
Patients who were hospitalized in the Covid ward and recovered from the acute phase of Covid-19 with no need of ICU admission. All patients had SARS-Cov-2 infection confirmed by positive PCR from nasopharyngeal swab. Neuropsychological study was performed on average 20 days after hospital discharge to have the most recent possible cognitive profile related to the infection. We enrolled 29 healthy controls (Covid-) who did not have SARS COV 2 infections with a 1:1 match by age, education and gender.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cognitive and neuropsychiatirc symptoms in Covid-19 patients
Prevalence of neuropsychological and neuropsychiatric impairment in patients after hospitalization in patients with Sars-Cov2 infection.
Time frame: About 20 days after hospital dismission
Plan to share: No
Ran from Jan 2021 to primary completion in May 2021, 4 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 4 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ospedale Generale Di Zona Moriggia-Pelascini